Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa

Sally Land, Julian Zhou, Philip Cunningham, Annette H Sohn, Thida Singtoroj, David Katzenstein, Marita Mann, David Sayer and Rami Kantor

Abstract

Background: The TREAT Asia Quality Assessment Scheme (TAQAS) was developed as a quality assessment programme through expert education and training, for laboratories in the Asia-Pacific and Africa that perform HIV drug-resistance (HIVDR) genotyping. We evaluated the programme performance and factors associated with high-quality HIVDR genotyping.

Methods: Laboratories used their standard protocols to test panels of human immunodeficiency virus (HIV)-positive plasma samples or electropherograms. Protocols were documented and performance was evaluated according to a newly developed scoring system, agreement with panel-specific consensus sequence, and detection of drug-resistance mutations (DRMs) and mixtures of wild-type and resistant virus (mixtures). High-quality performance was defined as detection of ≥95% DRMs.

Results: Over 4.5 years, 23 participating laboratories in 13 countries tested 45 samples (30 HIV-1 subtype B; 15 non-B subtypes) in nine panels. Median detection of DRMs was 88–98% in plasma panels and 90–97% in electropherogram panels. Laboratories were supported to amend and improve their test outcomes as appropriate. Three laboratories that detected 80% DRMs in early panels demonstrated subsequent improvement. Sample complexity factors – number of DRMs (p < 0.001) and number of DRMs as mixtures (p < 0.001); and laboratory performance factors – detection of mixtures (p < 0.001) and agreement with consensus sequence (p < 0.001), were associated with high performance; sample format (plasma or electropherogram), subtype and genotyping protocol were not.

Conclusion: High-quality HIVDR genotyping was achieved in the TAQAS collaborative laboratory network. Sample complexity and detection of mixtures were associated with performance quality. Laboratories conducting HIVDR genotyping are encouraged to participate in quality assessment programmes.

Keywords: HIV; drug resistance; genotyping; quality assessment.
effort: Linking African and Asian Societies for an Enhanced Response (LAASER) to HIV/AIDS, in partnership with the PharmAccess Foundation, International Civil Society Support and the AIDS Fonds [19]. While TASER is conducted in Asia, PharmAccess’ parallel Studies to Evaluate Resistance (PASER) conduct HIVDR studies in Africa [19]. With the rationale to support good quality and reliable HIVDR testing, TAQAS (TREAT Asia Quality Assessment Scheme), an EQA scheme for HIVDR genotyping, was established to support LAASER-related activities in the two regions [20]. TAQAS offered EQA of HIVDR genotyping with quantitative assessment of laboratory performance, educational feedback, follow-up of suboptimal results, trouble-shooting support and establishment of a laboratory network.

We previously described findings from the initial implementation of TAQAS within 10 laboratories over a 19-month period in 2005–2007, and demonstrated improvement or maintenance of high standards of genotyping outcomes [20]. The objectives of this study are to evaluate TAQAS performance following its expansion to include more laboratories, while testing additional EQA panels with diverse HIV-1 subtypes; develop a novel scoring system of test performance; and investigate predictors of HIVDR genotyping proficiency. A wide spectrum of laboratory expertise was included with the aim not only to evaluate, but also to improve the full spectrum of HIVDR genotyping performance, while creating a collaborative laboratory network and providing mentorship and support to emerging laboratories in RLS.

Materials and methods

Participating laboratories

TAQAS participants included laboratories that provided HIVDR genotyping for clinical TASER (n = 19 in 11 Asian countries) and PASER (n = 3 in 2 African countries) sites (Figure 1). A Virology Quality Assessment Program (VQA)-certified US laboratory with HIVDR genotyping expertise (Stanford University) participated in an “expert” capacity as a “positive control.”

Sample panels and testing

Over the 4.5-year study period (12/5–6/10), nine 5-sample TAQAS panels (45 samples) were distributed to and tested by participating laboratories, using their standard protocols. Panels were prepared by, shipped from and results returned to the NRL (Melbourne, Australia), an independent quality assurance provider.

Samples in seven panels were either: (i) plasma sourced from HIV-1-patients (27/35), or (ii) culture-amplified virus in HIV-negative plasma (8/35) (Table 1). Most samples contained multiple drug-resistance mutations (DRMs) and most were Subtype B sourced in Australia. Two panels (IV and VII) were pol electropherograms, derived from ARV-treated individuals, and used to account for inter-laboratory sequence production variation in HIVDR genotyping outcome. Panels varied in the number of DRMs; number of mixtures, defined as >1 nucleotide base at one position; and number of DRMs present as mixtures (Table 1). All plasma/virus samples (n = 35) had a viral load >1000 copies/mL; most (31/35) >10,000 copies/mL.

Samples were shipped biannually frozen on dry ice (plasma panels) or sent electronically (electropherogram panels) to TAQAS participants after obtaining necessary country-specific permits. Within five weeks of panel receipt, participants were required to return three result outputs: (i) FASTA nucleotide sequences; (ii) lists of DRMs; and (iii) predicted susceptibility to a standardized list of ARVs. Detailed genotyping information on testing methods was collected via an electronic “Protocol Questionnaire” (Supplementary File 1).

Figure 1. The location of TAQAS participants: China: Beijing, Shanghai, Hong Kong; India: Chennai, Pune; Japan: Tokyo (n = 2) Nagoya; Malaysia: Kota Bharu, Kuala Lumpur; Philippines: Manila; Singapore: Singapore; Taiwan: Taipei; South Korea: Seoul; Thailand: Bangkok (n = 3), Chiang Mai; Vietnam: Ho Chi Minh; Africa (not included in the map): Entebbe (n = 2), Johannesburg; USA (not included in map): reference laboratory.
Laboratory performance evaluation

Sequences returned underwent quality control and phylogenetic analyses to examine within-sample clustering using Sequence Quality Analysis Tool (SQUAT) [21]. Outlier sequences (bootstraps B 99%) that did not cluster appropriately were manually inspected for mutation motifs and mis-alignment, and if consistent, they were reported and omitted from further analyses.

HIVDR genotyping performance was evaluated against a panel-specific consensus sequence, termed the “target genotype” (TG), deduced by aligning sample-specific FASTA nucleotide sequences returned by all participants and applying an algorithm to identify the most likely consensus quasi-species detectable by DNA sequencing [22]. The algorithm considered that it was extremely unlikely for multiple participants to incorrectly sequence the same nucleotide at any single position; therefore, nucleotide mixtures reported by two or more participants were included in the TG. DRMs were defined as mutations listed in both the Stanford Resistance Database [23] and the International AIDS Society-USA list [24]. When participants were unable to return a complete set of panel results due to amplification or quality issues, analyses were executed only for completed samples that satisfied the quality control analyses.

Laboratory performance was scored using a system composed of eight criteria (Table 2). Performance was not evaluated by the scoring system if participants reported results from fewer than four out of five samples per panel because of failure to amplify sequences, and/or production of poor quality sequences as deemed by the participant.

### Table 1. TAQAS panels tested and detection of drug-resistance mutations by participants between December 2005 and June 2010

| TAQAS ID | Subtype(s) in panel | Mixtures in panel TG | DRM positions in pol region in panel TG | Median % DRM detected (range) |
|----------|----------------------|----------------------|-----------------------------------------|-----------------------------|
| I        | B                    | 73                   | V32M 46I 47V I54VM G73S V82A I84V L90M | 91 (80–96) |
| II       | B and D              | 48                   | M46I 47V I54LM G73S V82IS84V L90M | 98 (85–100) |
| III      | B and C              | 109                  | M46I 47V I54LM G73S V82IS84V L90M | 88 (55–97) |
| IV (e)   | A, B and CRF01_AE    | 46                   | M46I 47V I54LM G73S V82IS84V L90M | 97 (89–100) |
| V        | B and CRF07_BC       | 48                   | M46I 47V I54LM G73S V82IS84V L90M | 98 (96–100) |
| VI       | B                    | 68                   | M46I 47V I54LM G73S V82IS84V L90M | 97 (88–98) |
| VII (e)  | B                    | 113                  | M46I 47V I54LM G73S V82IS84V L90M | 90 (81–99) |
| VIII     | B                    | 172                  | M46I 47V I54LM G73S V82IS84V L90M | 89 (76–100) |
| IX       | B and CRF01_AE       | 119                  | M46I 47V I54LM G73S V82IS84V L90M | 98 (91–100) |

*Each panel consisted of five samples; Non-B subtype plasma samples included one Subtype A and one Subtype C from Uganda, one CRF07_BC from Taiwan and three CRF01_AE from Thailand. Non-B electropherogram samples included two Subtype A from Kenya and one CRF01_AE from Thailand; listed as mutations conferring HIV drug resistance in IAS-USA list and Stanford Database.

TG, target genotype; Mixtures: nucleotide mixtures; DRMs, drug-resistance mutations; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI; e, electropherogram sample format used in panel.
and/or the quality control analyses indicative of potential sample mix-up or contamination. “No Score” was by definition a poor performance outcome.

At the conclusion of each panel nucleotide sequence alignments, analyses and scores of all participants’ were made available on a password-protected website. Participants were encouraged to review and compare results, and, if necessary, amend and improve their methods. Sequence alignments were provided for participants whose performance was not scored and they were alerted to the reason. Resubmission of results was not permitted.

To provide support and follow-up, annual workshops were conducted for technical and scientific staff directly involved with HIVDR genotyping from participating laboratories, with detailed discussions and expert presentations of laboratory methods. This also facilitated development of a regional network of operators with a range of expertise. When suboptimal performance was identified, laboratories were asked to describe initiatives to address identified problems. In two cases, expert laboratory personnel from within the TAQAS network assisted in setting up HIVDR genotyping protocols or addressed recurring problems.

**Statistical model to predict quality of HIVDR genotyping outcome**

To evaluate participants’ HIVDR genotyping outcome, a binary endpoint was defined as detection of ≥95% (high-quality) vs. <95% (low-quality) of consensus DRMs in the TG. Factors potentially associated with panel complexity and laboratory performance were examined. Panel complexity was defined by: (i) number of DRMs in the TG; and (ii) number of DRMs present as mixtures in the TG; (iii) sample subtype (B or non-B); and (iv) sample format (plasma or

---

Table 2. Scoring system developed and applied to evaluate participants’ HIVDR genotyping outcome

| Criteria name                              | Criteria detail                                                                 | Penalty points                      | Evaluation context                                                                 |
|-------------------------------------------|--------------------------------------------------------------------------------|------------------------------------|------------------------------------------------------------------------------------|
| (i) Participation                          | Submission of any results                                                     | 10 points if fail to submit any result One point per week of late submission | Suitability of testing turnaround time for patient management and/or research purposes |
| (ii) Nucleotide sequence submission        | Submission of both PR and RT sequences                                       | One point for each failure to submit PR or RT sequences per sample; NO SCORE if sequences from <4 of 5 samples returned | Disqualified from analysis if insufficient or outlier sequence data are returned |
| (iii) Sequence clustering                  | Adequate sequence clustering with same-samples from other participants         | Five points per PR or RT inadequate clustering; NO SCORE if sequences from >4 of 5 samples do not cluster | Measures of technical aspects of HIVDR genotyping output |
| (iv) Nucleotide sequence agreement         | Level of agreement (%) with the complete target genotype (TG) (consensus sequence) | ≥ 99% agreement: 0 points 98 to <99% agreement: 2 points 95 to <98% agreement: 5 points 90 to < 95% agreement: 10 points <90% agreement: 15 points | |
| (v) Detection of DRMs                     | Detection (%) of DRMs in the TG (consensus sequence)                          | ≥ 95% detected: 0 points 90 to <95% detected: 2 points 85 to <90% detected: 5 points 80 to <85% detected: 10 points <80%: 15 points | |
| (vi) Reporting of DRMs                    | DRM(s) reported compared with majority                                         | Five points per DRM not reported | Peer group comparison of drug-resistance profile reported for patient management |
| (vii) Detection of mixtures                | Detection (%) of NMs in the TG (consensus sequence)                           | Not scored                          | |
| (viii) Reporting of drug-resistance profile| Agreed interpretation of drug resistance compared with majority when using a single interpretation system, e.g. Stanford Database | Assessed as high, moderate or low level of agreement | |

**Hurdle requirement**, participant must return sequence data from at least four of five samples that cluster with same-samples from other participants to be scored on their performance. “No Score” was by definition a poor performance outcome. *Included to highlight importance of detection of mixtures; not scored as variation in the detection of mixtures(%) was not proportional to detection of DRMs(%).

PR, protease; RT, reverse transcriptase; DRMs, drug-resistance mutations as in IAS-USA list and Stanford Database; TG, target genotype; mixtures, nucleotide mixtures.
Laboratory performance was defined by: (i) length of nucleotide sequence; (ii) nucleic acid agreement with TG; (iii) detection of DRMs in the TG; (iv) detection of mixtures in the TG; and (v) elements of HIVDR genotyping protocol (i.e. laboratory experience, throughput, time pressure, in-house or outsourced sequencing, nucleotide sequence editing practices and software used). Mixed-effect logistic regression models were used to derive the endpoint using panel complexity and laboratory performance as predictors. All results, including those from incomplete result sets, were included in the models. As laboratories participated in varying panels, and incomplete result sets were included, random-effect models were used to take into account variation both within and between laboratories. The final model included predictors that were significant at 0.10 level (two-sided). Data management and statistical analyses were performed using Stata (StataCorp, STATA 10.1 for Windows, College Station, TX, USA).

Results

Participating laboratories
Nine TAQAS panels were delivered to 19 laboratories in the Asia-Pacific, three in Africa and one in the United States (Figure 1). Eight laboratories reported results for all nine panels. Laboratories were recruited over time and on average reported results for six panels (Table 3). Inconsistent participation was due to cessation of HIVDR genotyping services (Lab 11), import restrictions (Lab 13), resource constraints such as reagents, staff or laboratory access shortfall (Labs 14 and 20), or an inability to process electropherograms due to software incompatibility (Labs 3, 7 and 13).

Protocol questionnaire
The Questionnaire, which was completed between the fifth and sixth panels by all but one laboratory (Lab 11 ceased HIVDR testing after Panel VI), demonstrated a wide variability in HIVDR genotyping experience. Laboratories were conducting HIVDR testing for a median of six years (IQR: 5.5 years; range: <1 to 14 years); the median testing throughput was 348 tests per annum (IQR: 625; range: 21 to >4000); and the median per sample turnaround time was 14 days (IQR: 14.5 days; range: 2–30 days). Fourteen laboratories required staff qualifications of a bachelor degree or higher and three required training in molecular biological technique (five did not respond). Time pressure to complete HIVDR testing was perceived by 9 out of 22 laboratories.

The majority of laboratories (18/22) used locally assembled protocols, with wide variations in primers, sequencing probes and input sample volume (data not shown). These aspects of the protocols were not compared. Four laboratories used commercial kits (TruGene® one laboratory; ViroSeq® three laboratories). The impact on test outcome of participants’ sequencing practices was assessed. Only a few laboratories (6/22) outsourced sequencing. Most laboratories (20/22) used an automatic base calling software and all reported manual checking and editing of automated base calls. In most laboratories (16/22), more than one person was involved in sequence editing. The peak height to call mixed electropherogram was defined by: (i) length of nucleotide sequence; (ii) nucleic acid agreement with TG; (iii) detection of DRMs in the TG; (iv) detection of mixtures in the TG; and (v) elements of HIVDR genotyping protocol (i.e. laboratory experience, throughput, time pressure, in-house or outsourced sequencing, nucleotide sequence editing practices and software used). Mixed-effect logistic regression models were used to derive the endpoint using panel complexity and laboratory performance as predictors. All results, including those from incomplete result sets, were included in the models. As laboratories participated in varying panels, and incomplete result sets were included, random-effect models were used to take into account variation both within and between laboratories. The final model included predictors that were significant at 0.10 level (two-sided). Data management and statistical analyses were performed using Stata (StataCorp, STATA 10.1 for Windows, College Station, TX, USA).

Table 3. Panels tested by TAQAS participants over a 4.5-year period

| Lab ID | I | II | III | IVb | V | VI | VIIb | VIII | IX |
|--------|---|----|-----|-----|---|----|------|------|----|
| 1*     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 2      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 3      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 4      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 5      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 6      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 7      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 8      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 9      | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 10     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 11     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 12     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 13     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 14     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 15     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 16     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 17     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 18     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 19     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 20     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 21     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 22     | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 23c    | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |
| 23c    | NP| NP | NP | NP  | NP| NP | NP   | NP   | NP |

*Stanford University Laboratory; belectropherogram panels; cLab 23 participated in only one panel; it was included in this presentation to show progressive laboratory enrolment.

NP, laboratory did not participate; DR, data removed from analysis because laboratory returned sequence from <4 of 5 samples or reported outlier sequence for >4 of 5 samples.

Table 3. Panels tested by TAQAS participants over a 4.5-year period

Bases was set at 20–30% by 19 laboratories. It was policy in most laboratories (15/22) to review sequence data at sites associated with ARV resistance. Twelve laboratories reported controlling for contamination using software such as Clustal (www.clustal.org) or Mega (www.megasoftware.net).

Of 18 laboratories that used in-house protocols, 15 used the Stanford Database for resistance interpretation and the remaining three used the Stanford Database in conjunction with IAS-USA [24] or ANRS systems [7]. The three laboratories that used Viroseq consulted the Stanford Database in addition to Viroseq guidelines. The laboratory that used TruGene relied solely on the manufacturer’s guidelines.

Laboratory performance
A total of 144 data sets were returned by the 23 participating laboratories; most within the specified turnaround time of five weeks; 10 participants returned results up to five weeks past the turnaround time for one (n = 9) or two (n = 1) panels. Late submission of results was recorded and these data sets were included in analyses. One hundred and...
Thirty six data sets (107 plasma and 29 electropherograms) were suitable for assessment. Eight data sets were removed from analyses because they were derived from less than four out of five samples per panel due to sequence amplification failures (two datasets); production of sequence deemed of poor quality (three data sets); or did not satisfy quality control analyses (three data sets) (Table 3). On follow-up, the two laboratories with outlier sequences achieved a non-outlier result by either re-sequencing and changing training protocols; or by preparing new batches of primers and reagents. Revised test outcomes were not re-scored.

The median detection of DRMs in the TG in the seven plasma panels ranged between 88% and 98% (Table 1). In most reported data sets (102/107), the number of DRMs detected was above the median minus two standard deviations (median \(-2SD\)) in each panel. The lowest levels of detection of DRMs were in Panels III (88%), VIII (89%) and I (91%), which had the highest proportion of DRMs presented as mixtures (45%, 30% and 24%, respectively). Although overall detection of DRMs was high throughout the study period, some performance improvement was observed over time. Three laboratories detected <80% of DRMs in early panels but subsequently demonstrated improved performance (Labs 7, 13 and 22; Figure 2). The observed considerable intra- and inter-laboratory variation in the detection of mixtures did not correlate with the percentage of DRMs detected. However, the two laboratories that consistently reported low levels of mixtures or none (Labs 2 and 5; Figure 3) both detected less than the median \(-2SD\) deviations of TG DRMs in two panels, and both had a tendency to underreport the DRMs reported by the majority of participants (data not shown).

The median detection of DRMs in the electropherogram panels was 97% and 90%. Again, detection of mixtures varied (Panel IV: 0–89% with 11 participants; Panel VII: 1–79% with 20 participants). Labs 2 and 5 detected low levels of mixtures in the electropherogram panels (Figure 3). In addition Lab 5’s detection of DRMs in Panel 4 was below the mean \(-2SD\). When data from Labs 2 and 5 were removed, the range in the detection of mixtures decreased: Panel IV: 29–89% with 9 participants; Panel VII: 18–79% with 18 participants. TREAT Asia and TAQAS have worked with Labs 2 and 5 addressing software training in detection of mixtures. Lab 2’s detection of mixtures increased (from \(\leq 1\) to \(39\%\) in Panel IX; Figure 3).

**Score as a measurement of performance**

Data sets from all participants were quantitatively evaluated using the scoring system (Table 2). High-quality test outcome, defined as detection of \(\geq 95\%\) of the DRMs in the TG, was associated with scoring criteria related to technical aspects of HIVDR genotyping, including adequate phylogenetic clustering, sequence alignment and level of agreement with the TG, and detection of TG DRMs (Table 2, Criteria iii, iv and v; \(p < 0.05\)).

**Predictors of HIVDR genotyping performance**

Factors associated with laboratory performance that had an impact on HIVDR genotyping outcome included mixture detection (OR: 19.8; \(p < 0.001\)) and level of agreement with the TG (OR: 46.5 for 98-99% agreement, \(p = 0.002\); and OR:

![Figure 2. Detection of drug-resistance mutations according to the target genotype (TG) in nine TAQAS panels (one graph per laboratory).](image-url)
for ≥ 99% agreement, \( p < 0.001 \) (Table 4). Neither length of sequence nor between-laboratory differences in HIVDR genotyping sequencing protocols were associated with performance. Factors associated with panel complexity that had an impact on HIVDR genotyping outcome included number of TG DRMs (OR 31.7; \( p < 0.001 \)), and number of DRMs present as mixtures (OR: 19.1 for 11-15 DRMs as mixtures, \( p < 0.001 \); and OR: 240 for ≤10 DRMs as mixtures, \( p < 0.001 \)). Subtype (B or non-B) and sample format (plasma or electropherogram) were not associated with genotyping performance.

**Discussion**

We report extended results from TAQAS, an EQA programme for HIVDR genotyping by a group of laboratories in Asia-Pacific and Africa [20]. Twenty-two laboratories (not including the certified US laboratory) from 13 countries demonstrated proficient HIVDR genotyping of 45 HIV-1 multi-subtype samples in nine panels, as evidenced by a low level of amplification failure; minimal sample cross-contamination; high levels of DRMs detection and sequence homology to consensus sequences; and compliance with a test turnaround time indicating provision of results in a clinically relevant timeframe. Intra-and inter-laboratory variation in detection of mixtures was observed, and in some laboratories was associated with sub-optimal detection and reporting of DRMs. HIVDR genotyping execution was associated with panel complexity factors including numbers of DRMs and DRMs occurring as mixtures, and with laboratory performance factors including detection of mixtures and agreement with TG, but not with differences in laboratories’ use of commercial vs. in-house tests or sequencing protocols. A new scoring system showed that quality of test outcome was related to technical proficiency in HIVDR genotyping. In contrast to other EQA programmes [8,22,25–28], TAQAS

| Panel # | % Detection of NMs |
|---------|---------------------|
| 1       | I                   |
| 2       | II                  |
| 3       | III                 |
| 4       | IV                  |
| 5       | V                   |
| 6       | VI                  |
| 7       | VII                 |
| 8       | VIII                |
| 9       | IX                  |
| 10      | I                   |
| 11      | II                  |
| 12      | III                 |
| 13      | IV                  |
| 14      | V                   |
| 15      | VI                  |
| 16      | VII                 |
| 17      | VIII                |
| 18      | IX                  |
| 19      | I                   |
| 20      | II                  |
| 21      | III                 |
| 22      | IV                  |
| 23      | V                   |
| 24      | VI                  |
| 25      | VII                 |
| 26      | VIII                |
| 27      | IX                  |

**Table 4. Predictors of high-quality HIV drug-resistance genotyping outcome**

| Covariate                                    | Odds ratio (95% CI) | \( p \)  |
|----------------------------------------------|---------------------|---------|
| Laboratory performancea                       |                     |         |
| Mixtures detected (%)                        | 1.00                |         |
| ≤50b                                         |                     |         |
| >50b                                         | 19.78 (4.16, 94.09) | <0.001  |
| Agreement with nucleotide sequence           | 1.00                |         |
| <98%ab                                       |                     |         |
| 98 to <99%ab                                 | 46.54 (3.87, 559.51)| 0.002   |
| ≥99%ab                                       | 129.41 (10.32, 1622.32)| <0.001 |
| Panel complexity                              |                     |         |
| Number of DRMs as mutants                     | 1.00                |         |
| ≤40b                                         |                     |         |
| >40b                                         | 31.66 (6.92, 144.81)| <0.001  |
| Number of DRMs as mixtures                   | 1.00                |         |
| >15b                                         |                     |         |
| 11–15b                                       | 19.10 (3.43, 106.39)| 0.001   |
| ≤10b                                         | 239.95 (27.89, 2064.56)| <0.001 |

aCompared with target genotype (TG); breference category.
participants were supported to address testing deficiencies, and their performance improved in subsequent panels. The programme’s feedback in response to suboptimal performance and its educationally oriented approach may have contributed to the high quality of the testing outcomes.

Similar to other EQA programmes, TAQAS participants varied in testing experience and access to technical resources [25,29]. In contrast to other studies where laboratories predominantly used commercial kits and consensus protocols and no difference in test outcome was found, the majority of TAQAS participants used a variety of in-house technologies, as well as several sequence editing software programmes [5,25,30,31]. However, most participants had similar sequence editing practices and used the Stanford Database for interpretation. Based on these data, low-cost in-house assembled assays can successfully be used for HIVDR testing with the support of EQA programmes. EQA programmes should aim to assess the HIVDR laboratory testing process using clinically relevant sample types. The predominant use of plasma samples in TAQAS enabled assessment of detection of viral mixtures, important in DRM detection [6,8,20,32], and useful in the assessment of inter-laboratory testing variation [33]. The use of a sample type with inherent variability like plasma, in contrast to clones or plasmids, mandated the use of a TG rather than a sequence derived by a reference laboratory [10,25,30]. While inter-laboratory comparison is complicated by inclusion of samples with mixtures in EQA panels, the laboratory’s ability to detect mixtures is an important measure of the quality of the genotyping output and every effort should be made to monitor and support this in an EQA programme [5].

Subtle differences in EQA programmes that reported higher levels of DRM detection than reported by TAQAS participants are noted [25,27,29–31]. Some programmes report on the distribution of a single panel or low-sample-number panels, and/or use virus derived from viral culture supernatant, cloned or extracted material as the sample format. Such programmes could expect higher detection levels of DRMs compared to those seen with clinical samples, due to differences in sample variability. Indeed, comparable detection of DRMs to that seen in TAQAS was reported in a four-plasma-sample distribution to 20 laboratories [28]. Similarly, panels incorporating non-subtype B samples, as in TAQAS, can affect sequence variability and TG concordance, due to inter-subtype genetic differences. Such samples should be included in EQA panels, particularly for laboratories in settings where non-B subtypes predominate.

Panel complexity, detection of mixtures and level of sequence agreement were found to predict HIVDR genotyping quality, confirming previous reports [5,20,25,28,30,34,35]. The electropherogram samples used in two TAQAS panels showed that variation in detection of mixtures can occur because of inter-laboratory differences post-sequence production, rather than genotyping extraction, amplification and sequencing protocols. Sequence editing has been suggested to contribute to disparity in HIVDR genotyping outcomes particularly with respect to the mixtures detection [36]. However, while there was variation in sequence editing software used, most participants adhered to common, high standards to edit raw sequence data. This may account for the lack of association between the quality of the test outcome and sequence editing practices demonstrated by this group. Sequences with a high number of mixtures should be incorporated into EQA panels, and laboratories should be encouraged to develop proficiency in mixture calling, which is directly related to identification of DRM.

Objective assessment of EQA performance outcomes enables intra- and inter-laboratory and between-panel comparison, and potentially comparison between EQA programmes [5,25,31,37]. The TAQAS scoring system described here extends systems previously reported, by adding a measure of clinical utility; a hurdle requirement of the production of good quality, sample-specific sequence thereby emphasizing the importance of quality control measures as performance indicators; detection and reporting of all consensus DRMs and DRMs presented as mixtures; and the interpretation of ARV resistance as per the peer group majority [5,25,26,31,37]. Scores on technical aspects of testing were associated with the quality of test outcome. Scoring multiple test components improved the value of the EQA exercise for participants by flagging possible causes of suboptimal performance. Objective measurement of test outcomes enables fair, on-going assessment of participants’ EQA outcomes that may be required for auditing, by funding bodies and for participation in multi-centre clinical trials.

Some previously reported limitations of TAQAS [20] have been addressed here. Information about participants’ testing procedures was documented, the number of participants more than doubled and criteria against which HIVDR genotyping outcomes were assessed were defined. Existing limitations include lack of ability to compare genotyping technologies among participants, as most used in-house assays [25]. These are realistic circumstances in cost-constrained settings. The inclusion of non-B and recombinant viruses relevant to Asia has increased, though not sufficiently to assess the impact of different subtypes on test outcomes [30]. The importance of including such samples is acknowledged [5] although other EQA providers have provided predominantly subtype B samples [30,31,35].

TAQAS was established to build capacity for and assure quality of HIVDR genotyping to support clinical care and research in Asia and Africa. Participation by 22 laboratories over an extended timeframe confirmed their HIVDR testing proficiency. Several reasons are proffered as to the high-quality test outcomes of this complicated test: diligent and conscientious attitude of participants, provision of complex clinical samples, comprehensive and comparative analysis of results, follow-up initiatives after suboptimal performance, and support and information dissemination by TREAT Asia and NRL. TAQAS facilitated successful application of a quantitative measure of laboratory performance of HIVDR genotyping and identification of predictors of test quality. Both tools can improve utility of future EQA programmes. The importance of continuous EQA participation to maintain and improve HIVDR genotyping outcome has been validated [8,25,30]. Recent reports provide novel methods to standardize the interpretation of electropherograms for HIVDR testing [38,39]. Though promising, it will take time until such
methods are incorporated into laboratories’ protocols. As methods are developed and modified, their incorporation into high quality assessment programmes will be essential. As demonstrated by TAQAS, quality assessment programmes not only assess proficiency but can also be harnessed to establish, expand and improve testing, and be used as a vehicle for educational initiatives and the creation of collaborative and educational testing laboratory networks.

Authors’ affiliations
1NRL, Melbourne, Australia; 2The Kirby Institute, University of New South Wales, Sydney, Australia; 3St Vincent’s Hospital Sydney Limited, Sydney, Australia; 4TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand; 5Department of Medicine, Division of Infectious Disease, Stanford University, Stanford, CA, USA; 6Division of Infectious Diseases, Department of Medicine, Warren Alpert Medical School, Brown University, Providence RI, USA; 7Conexio Genomics, Fremantle, Western Australia, Australia

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Sally Land, Julian Zhou, Philip Cunningham, Annette H Sohn, David Katzenstein and Rami Kantor conceived and designed the study protocol. Philip Cunningham, David Katzenstein, David Sayer and Rami Kantor provided expert training to participants. Thida Sirirajtho coordinated panel and workshop logistics. David Sayer, Marita Mann and Rami Kantor undertook phylogenetic and sequence analyses. Julian Zhou realized the statistical analysis. Sally Land conducted the data analysis, wrote the first draft of the manuscript and worked with Rami Kantor to finalize the writing. Sally Land, Rami Kantor, Annette H Sohn, and David Katzenstein critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
TAQAS is an initiative of TREAT Asia, a programme of amfAR. The Foundation for AIDS Research, and is supported in part by amfAR with additional support from the Dutch Ministry of Foreign Affairs through a partnership with Stichting Aids Fonds. The Kirby Institute for infection and immunity in society is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine of The University of New South Wales. The content of this publication is, however, solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.

The TAQAS Laboratory Network: L Kang, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China; WC Yam and J Chen, HIV Molecular Biology Laboratory, Department of Microbiology, Queen Mary Hospital, Hong Kong; S Olka and X Bi, AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan; W Sugiuira, National Institute of Infectious Diseases, Tokyo, Japan; N Kumarsamy, V Madhavan and S Saravanan, Infectious Diseases Laboratory, YRG Centre for AIDS Research and Education, Chennai, India; KP Ng and A Kamarulzaman, HIV Research Laboratory, Centre of Excellence for Research in AIDS (CEREA), University of Malaya, Kuala Lumpur, Malaysia; W Stevens and C Wallis, National Health Laboratory Services (NHLS) – University of Witwatersrand, Johannesburg, South Africa; YMA Chen and Yi Chen, AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan; R Sutthent, Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand; K Ruxrunghen and S Sirivichayakul, Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; W Chanthratta, W Pijroj and C Wattipun, Virology and Molecular Microbiology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; D Katzenstein and M Balamean, Center for AIDS Research, Division of Infectious Diseases and Geographic Medicine, Stanford University, CA, USA; TTX Lien and TC Thanh, HIV/AIDS laboratory, Pasteur Institute in Hochimin City, Ho Chi Minh City, Vietnam; F Kyeyune and L Bagenda, CFAF Molecular Biology Laboratory, Joint Clinical Research Centre (JCRC), KAMPALA, Uganda; J Praparratanaporn and T Sirisanthana, HIV-1 Genotyping Drug Resistance Laboratory, Faculty of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; PN Mukhodaphaya and A Acharya Medical Genetics Division, geneOmbio Technologies, Pune, India; J Hattori and W Sugira, Department of Infection and Immunology, Clinical Research Center, National Nagoya Medical Center, Nagoya, Japan; E Segure-Mercado and R Ditangco, Molecular Biology Laboratory, Research Institute for Tropical Medicine, Manila, Philippines; H Zhou and H Zeng, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; KK Chew and QT Ng, Infectious Disease Research Laboratory, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore; JY Choi, AIDS Research Institute, Yonsei University College of Medicine, Seoul, South Korea; N Ndembi and F Lyagoba, MRC/UVRI Uganda Research Unit on AIDS,Entebbe, Uganda, ZZ Derris and S Mohamad Medical Microbiology and Parasitology, Health Campus, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.

References
1. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization’s global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl 2):1–13.
2. Wainberg MA, Zarobatin GB, Brenner DG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365(7):637–46.
3. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 4/2/12. [Internet]. 2012 [cited 2012 May 1]. Available from: http://www.aidsinfo.nih.gov/guidelines.
4. International bioinformatics workshop on virus evolution and molecular epidemiology. [Internet]. 2012 [cited May 2012]. Available from: http://regaweb.med.kuleuven.be/workshop/
5. Parkin N, Bremer J, Bertagnolio S. Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007–2010. Clin Infect Dis. 2012;54(Suppl 4):S266–72.
6. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society–USA panel. Clin Infec Dis. 2008; 47(2):266–85.
7. ANRS. [Internet]. 2012 [cited Aug 8]. Available from: http://www.hivrenchresistance.org
8. Schuurman R, Demeter L, Reichelderfer P, Tijjeng J, De Groot T, Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 1999;37:2291–6.
9. Bartlett W, Garrido E, Wallis C, Tucker SK, Noordeen H. Lymphocytosis and large intrathoracic airway obstruction. Spine (Phila PA1976). 2009; 34(1):55–65.
10. Saravanan S, Madhavan V, Kantor R, Sivamalar S, Gomathi S, Solomon SS, et al. Unusual Insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment- failing South Indian patients: association with other resistance mutations. AIDS Res Hum Retroviruses. 2012;28(7):1007–13.
11. Dross S, Chung M, Karie J, John-Stewart G, Overbaugh J, Sakr S, et al. NVP and 3TC-resistant HIV-1 detected in antiretroviral-naïve Kenyans initiating NNRTI-based ART. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011.
12. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, Gordon M, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS. 2010; 24(7):1007–12.
13. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical epidemiology. [Internet]. [cited 2012 May 1]. Available from: http://regaweb.med.kuleuven.be/workshop/.
14. Hamers LR, Deldeinski I, van Vught M, Stevens W, Rinke de Wit TF, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008; 13(5):625–39.
15. TREAT Asia. [Internet]. 2012 [cited May 2012]. Available from: http://www.aidsinfo.nih.gov/treatasia/.
16. Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, Borroto-Esoda K, et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naïve individuals undergoing efavirenz-containing therapy. AIDS. 2011;25(3):325–33.
17. Halvas EK, Alfordoni GM, Balfe P, Beck IA, Boltz VF, Coffin JM, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol. 2006;44(7):2612–6.
18. Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, U PC, Kansongp R, et al. Drug resistance mutations among antiretroviral-naïve HIV-1-infected patients in Asia: results from the TREAT Asia studies to evaluate resistance-monitoring study. Clin Infect Dis. 2011;52(8):1053–7.
19. Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antiviral Ther. 2009;14(5):619–29.

20. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods. 2009;159(2):185–93.

21. Delong AK, Wu M, Bennett D, Parkin N, Wu Z, Hogan JW, et al. Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase. AIDS Res Hum Retroviruses. 2012;28(8):894–901.

22. Sayer DC, Land S, Gizzarelli L, French M, Hales G, Emery S, et al. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J Clin Microbiol. 2003;41(1):227–36.

23. Shafer R. Stanford HIV sequence database. [Internet]. [cited 2012 May 1]. Available from: http://hivdb.stanford.edu

24. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17(5):138–45.

25. Pantid A, Mackay WG, Steel C, van Loo AM, Schuurman R. HIV-1 drug resistance genotyping quality assessment: results of the ENVA7 genotyping proficiency programme. J Clin Virol. 2008;43(4):401–6.

26. VQA. [Internet]. [cited 2013 Feb 9]. Available from: https://www.hanc.info/labs/abresources/vqaResources/ptProgram/Pages/default.aspx

27. Neuwald PD, Funelas MB, DelCarmen JP, Raybold AW, Jorgensen PA. Results of the 2001 AcroMetrix HIV-1 resistance proficiency program. J Clin Virol. 2002;25(Suppl 3):S55–63.

28. Korn K, Reil H, Walter H, Schmidt B. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol. 2003;41(8):3559–65.

29. Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, Koike T, et al. Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis. 2007;60(2–3):113–7.

30. Descamps D, Dehaegher C, Masquelier B, Ruffault A, Marcellin AG, Izaepet J, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol. 2006;78(2):153–60.

31. Souza DC, Sucupira MC, Brindeiro RM, Fernandez JC, Sabino EC, Incencio LA, et al. The Brazilian network for HIV-1 genotyping external quality control assurance programme. J Int AIDS Soc. 2011;14:45.

32. Erali M, Page S, Reimer LG, Hillyard DR. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol. 2001;39(6):2157–65.

33. Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, et al. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007;79(11):1617–28.

34. Huang DD, Bremer JW, Brambilla DJ, Palumbo PE, Aldrovandi G, Ehleman S, et al. Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays. J Clin Microbiol. 2005;43(8):3963–70.

35. Xu S, Li J, Bao Z, Xing H, Zhong P, Li H, et al. Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China. Mol Diagn Ther. 2010;14(1):31–41.

36. Huang DD, Eshleman SH, Brambilla DJ, Palumbo PE, Bremer JW. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J Clin Microbiol. 2002;40(1):3265–72.

37. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002;18(4):3265–72.

38. Struck D, Wallis CL, Denisov G, Lambert C, Servais JY, Viana RV, et al. Automated sequence analysis and editing software for HIV drug resistance testing. J Clin Virol. 2012;54(1):30–5.

39. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wyerhoven B, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol. 2012;50(6):1936–42.